A Study to Evaluate the Pharmacokinetics of BMS-986165 Administered as Various Prototypic Solid Tablet Formulations in Healthy Subjects
Latest Information Update: 13 Apr 2020
At a glance
- Drugs Deucravacitinib (Primary)
- Indications Autoimmune disorders; Crohn's disease; Inflammatory bowel diseases; Liver disorders; Plaque psoriasis; Psoriatic arthritis; Systemic lupus erythematosus; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 23 Mar 2020 Status changed from active, no longer recruiting to completed.
- 05 Mar 2020 Status changed from recruiting to active, no longer recruiting.
- 11 Feb 2020 New trial record